Article Text
Editorial commentary
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
Statistics from Altmetric.com
Footnotes
Contributors HM drafted the text, and MM and SK supervised and made revisions.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.